Animal models for Lassa virus infection

Frame, 1970, Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings, Am J Trop Med Hyg, 19, 670, 10.4269/ajtmh.1970.19.670

Monath, 1974, Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone, Science, 185, 263, 10.1126/science.185.4147.263

Olayemi, 2016, New Hosts of The Lassa Virus, Sci Rep, 6, 10.1038/srep25280

Bowen, 2000, Genetic diversity among Lassa virus strains, J Virol, 74, 6992, 10.1128/JVI.74.15.6992-7004.2000

Manning, 2015, Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage, Front Microbiol, 6, 10.3389/fmicb.2015.01037

Hallam, 2018, Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development, NPJ Vaccines, 3, 10.1038/s41541-018-0049-5

Whitmer, 2018, New lineage of Lassa virus, Togo, 2016, Emerg Infect Dis, 24, 599, 10.3201/eid2403.171905

Ortiz-Riano, 2013, Arenavirus reverse genetics for vaccine development, J Gen Virol, 94, 1175, 10.1099/vir.0.051102-0

Martinez-Sobrido, 2017, Lassa virus reverse genetics, Methods Mol Biol, 1602, 185, 10.1007/978-1-4939-6964-7_13

McCormick, 1986, Lassa fever. Effective therapy with ribavirin, N Engl J Med, 314, 20, 10.1056/NEJM198601023140104

Bausch, 2010, Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever, Clin Infect Dis, 51, 1435, 10.1086/657315

Ilori, 2019, Increase in Lassa fever cases in Nigeria, January-March 2018, Emerg Infect Dis, 25

Ehlkes, 2017, Management of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016, Euro Surveill, 22, 10.2807/1560-7917.ES.2017.22.39.16-00728

Kofman, 2019, Lassa fever in travelers from West Africa, 1969-2016, Emerg Infect Dis, 25, 245, 10.3201/eid2502.180836

Marien, 2017, No measurable adverse effects of Lassa, Morogoro and Gairo arenaviruses on their rodent reservoir host in natural conditions, Parasit Vectors, 10, 210, 10.1186/s13071-017-2146-0

Jahrling, 1982, Pathogenesis of Lassa virus infection in guinea pigs, Infect Immun, 37, 771, 10.1128/IAI.37.2.771-778.1982

Bell, 2017, Temporal progression of lesions in guinea pigs infected with Lassa virus, Vet Pathol, 54, 549, 10.1177/0300985816677153

Safronetz, 2015, The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset, Sci Rep, 5, 10.1038/srep14775

Gary, 2019, Lassa virus targeting of anterior uvea and endothelium of cornea and conjunctiva in eye of guinea pig model, Emerg Infect Dis, 25, 10.3201/eid2505.181254

Liu, 2018, Persistence of Lassa virus associated with severe systemic arteritis in convalescing guinea pigs (Cavia porcellus), J Infect Dis, 10.1093/infdis/jiy641

Carrion, 2007, Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues, J Virol, 81, 6482, 10.1128/JVI.02876-06

Callis, 1982, Pathology of Lassa virus infection in the rhesus monkey, Am J Trop Med Hyg, 31, 1038, 10.4269/ajtmh.1982.31.1038

Safronetz, 2013, A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques, J Infect Dis, 207, 1316, 10.1093/infdis/jit004

Baize, 2009, Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys, J Virol, 83, 5890, 10.1128/JVI.01948-08

Cashman, 2018, Immune-mediated systemic vasculitis as the proposed cause of sudden-onset sensorineural hearing loss following Lassa Virus exposure in cynomolgus macaques, MBio, 9, 10.1128/mBio.01896-18

Jahrling, 1980, Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin, J Infect Dis, 141, 580, 10.1093/infdis/141.5.580

Rosenke, 2018, Use of favipiravir to treat Lassa virus infection in macaques, Emerg Infect Dis, 24, 1696, 10.3201/eid2409.180233

Meraz, 1996, Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway, Cell, 84, 431, 10.1016/S0092-8674(00)81288-X

Hwang, 1995, A null mutation in the gene encoding a type I interferon receptor component eliminates antiproliferative and antiviral responses to interferons alpha and beta and alters macrophage responses, Proc Natl Acad Sci U S A, 92, 11284, 10.1073/pnas.92.24.11284

Durbin, 1996, Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease, Cell, 84, 443, 10.1016/S0092-8674(00)81289-1

Sato, 2001, The interferon system and interferon regulatory factor transcription factors – studies from gene knockout mice, Cytokine Growth Factor Rev, 12, 133, 10.1016/S1359-6101(00)00032-0

Schoggins, 2014, Interferon-stimulated genes: roles in viral pathogenesis, Curr Opin Virol, 6, 40, 10.1016/j.coviro.2014.03.006

van den Broek, 1995, Immune defence in mice lacking type I and/or type II interferon receptors, Immunol Rev, 148, 5, 10.1111/j.1600-065X.1995.tb00090.x

Muller, 1994, Functional role of type I and type II interferons in antiviral defense, Science, 264, 1918, 10.1126/science.8009221

Rieger, 2013, Infection of type I interferon receptor-deficient mice with various old world arenaviruses: a model for studying virulence and host species barriers, PLoS One, 8, 10.1371/journal.pone.0072290

Yun, 2012, Functional interferon system is required for clearance of Lassa virus, J Virol, 86, 3389, 10.1128/JVI.06284-11

McCormick, 1986, Lassa virus hepatitis: a study of fatal Lassa fever in humans, Am J Trop Med Hyg, 35, 401, 10.4269/ajtmh.1986.35.401

Yun, 2015, Animal model of sensorineural hearing loss associated with Lassa virus infection, J Virol, 90, 2920, 10.1128/JVI.02948-15

Oestereich, 2016, Chimeric mice with competent hematopoietic immunity reproduce key features of severe Lassa fever, PLoS Pathog, 12, 10.1371/journal.ppat.1005656

Pascolo, 1997, HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice, J Exp Med, 185, 2043, 10.1084/jem.185.12.2043

Arnold, 1991, MHC class-I transgenic mice, Annu Rev Immunol, 9, 297, 10.1146/annurev.iy.09.040191.001501

Flatz, 2010, T cell-dependence of Lassa fever pathogenesis, PLoS Pathog, 6, 10.1371/journal.ppat.1000836

Oestereich, 2016, Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever, J Infect Dis, 213, 934, 10.1093/infdis/jiv522

Liao, 1992, Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: evidence for viral cause, Otolaryngol Head Neck Surg, 106, 226, 10.1177/019459989210600303

Mateer, 2018, Lassa fever-induced sensorineural hearing loss: a neglected public health and social burden, PLoS Negl Trop Dis, 12, 10.1371/journal.pntd.0006187

Edington, 1972, The pathology of Lassa fever, Trans R Soc Trop Med Hyg, 66, 381, 10.1016/0035-9203(72)90268-4

Winn, 1975, Lassa virus hepatitis. Observations on a fatal case from the 1972 Sierra Leone epidemic, Arch Pathol, 99, 599

Zinkernagel, 1986, T cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. Liver cell destruction by H-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay?, J Exp Med, 164, 1075, 10.1084/jem.164.4.1075

Mongkolsapaya, 2003, Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever, Nat Med, 9, 921, 10.1038/nm887

Kainulainen, 2018, Use of a scalable replicon-particle vaccine to protect against lethal Lassa virus infection in the guinea pig model, J Infect Dis, 217, 1957, 10.1093/infdis/jiy123

Morrison, 1989, Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus, Virology, 171, 179, 10.1016/0042-6822(89)90525-4

Safronetz, 2015, A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses, PLoS Negl Trop Dis, 9, 10.1371/journal.pntd.0003736

Cashman, 2017, DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs, Hum Vaccin Immunother, 13, 3010, 10.1080/21645515.2017.1382780

Jahrling, 1984, Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain, Infect Immun, 44, 528, 10.1128/IAI.44.2.528-533.1984

Cashman, 2017, A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever, Hum Vaccin Immunother, 13, 2902, 10.1080/21645515.2017.1356500

Mire, 2017, Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever, Nat Med, 23, 1146, 10.1038/nm.4396

Geisbert, 2005, Development of a new vaccine for the prevention of Lassa fever, PLoS Med, 2, 10.1371/journal.pmed.0020183

Simmons, 1993, Lassa fever and sudden hearing loss, Otolaryngol Head Neck Surg, 109